Work

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Year: 2011

Type: article

Study design: Clinical Trial

Source: Diabetologia

DOI: 10.1007/s00125-011-2317-z

Authors: S. L. Samson, P. Sathyanarayana, M. Jogi, E. V. Gonzalez, A. Gutierrez, R. Krishnamurthy, R. Muthupillai, L. Chan, M. Bajaj

Institutions: Baylor College of Medicine, Baylor St. Luke's Medical Center

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Diabetes Association, American Diabetes Association Research Foundation, Eli Lilly and Company, Amylin Pharmaceuticals, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Molecular Medicine Scholars Training Grant, Animal Models for Lipid Metabolism , Diabetes Endocrinology Research Center

OpenAlex ID: W2040507318

FWCI: 3.21

Cites: 21

Cited by: 110

Related to: 10